Is Ozempic and Wegovy the Same Medicine?

Do Ozempic and Wegovy contain the same active ingredient?

Yes. Both products are semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist made by Novo Nordisk. Semaglutide works by mimicking a gut hormone that signals fullness, slows how quickly the stomach empties, and influences blood-sugar regulation. At that biochemical level, the molecule in the Ozempic pen and the molecule in the Wegovy pen are identical.

What separates them is everything else: the licensed indication, the approved dose range, the regulatory history, and the clinical evidence that underpins each authorisation. The MHRA licenses medicines for specific uses based on specific trial programmes. Semaglutide was first trialled and approved for type 2 diabetes as Ozempic, then later studied at higher doses in the STEP programme (published in the New England Journal of Medicine) and subsequently licensed at those higher doses for weight management as Wegovy. Two products, one molecule, two separate authorisations.

This is not unusual in pharmaceutical history, but it creates real confusion when people see both names in the press and assume they can use whichever is cheaper or easier to find. They cannot, legally or safely, without clinical oversight.

You can read more about how the two products compare in detail on our Wegovy versus Ozempic comparison page.

If they are the same drug, why does the licensed indication matter so much?

The licensed indication is not a technicality. It reflects the clinical evidence submitted to the regulator and the patient population that evidence was studied in. Ozempic's trials focused on adults with type 2 diabetes; Wegovy's STEP trials focused on adults with obesity or overweight and weight-related conditions, largely without diabetes. The doses studied were also different, and dose is where the two products diverge most sharply in practice.

Ozempic is approved up to 1mg or 2mg weekly. Wegovy's standard maintenance dose is 2.4mg, and the MHRA approved a 7.2mg maintenance option in January 2026, with a dedicated single-dose 7.2mg pen confirmed on 14 April 2026. The titration schedules reflect those higher targets: Wegovy starts at 0.25mg and steps up roughly every four weeks under prescriber supervision, reaching doses that Ozempic's licence does not cover.

Prescribing Ozempic for weight management (sometimes called off-label use) is not what its UK authorisation supports. The NHS medicines page for semaglutide sets this out clearly: Ozempic is for type 2 diabetes, Wegovy is for weight management. A clinician prescribing the wrong product for the wrong indication is acting outside UK licensing guidance, which also has implications for liability and patient safety.

The specific question of whether they are exactly interchangeable is worth reading in full on our page covering that precise distinction.

So what is actually licensed in the UK for weight loss?

Two medicines are currently licensed in the UK specifically for weight management in adults: Wegovy (semaglutide) and Mounjaro (tirzepatide). Both require a prescription following a clinical assessment. Neither can be legally dispensed without one.

Wegovy is a weekly injection, licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure or dyslipidaemia. Mounjaro is a dual GIP and GLP-1 receptor agonist (the only medicine in that class licensed in the UK) and holds a similar eligibility profile. You can explore how both work on our Wegovy weight-loss medicine page or read a broader overview of semaglutide as a treatment.

Ozempic does not appear on that list. Whatever someone reads on social media or hears from a friend who bought it abroad, Ozempic is not a licensed weight-loss medicine in the UK. Treating it as one means using a product outside its authorisation, often sourced through unverified channels, without the clinical review that a prescription process provides. The MHRA has repeatedly warned about counterfeit and illegally traded weight-loss pens, and a significant proportion of those seized have been mislabelled or contaminated. If you are wondering whether taking Ozempic and Wegovy at the same time is possible, our dedicated page explains exactly why that is not a safe or supported approach.

For a straightforward look at weight-loss treatment options that are actually licensed here, or to see current treatment costs, our Wegovy price page covers the private market honestly. Anyone who wants to know whether they'd be suitable for Wegovy or Mounjaro can get that answered through a consultation, our prescribers review every case the same day it arrives, not a queue for automated software. If you have further questions before starting, our FAQs cover the most common ones.

These are prescription-only medicines. A prescriber decides suitability based on your full medical picture. If you'd like to speak to our prescribers about which licensed option might suit you, you can start your free consultation here.